The relative susceptibility of mouse strains to pulmonary Cryptococcus neoformans infection is associated with pleiotropic differences in the immune response

Infection and Immunity

Volumn 75, Issue 6, 2007, Pages 2729-2739

  Zaragoza, Oscar ^a,b   Alvarez, Mauricio ^a   Telzak, Andrew ^a   Rivera, Johanna ^a   Casadevall, Arturo ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; GLUCURONOXYLOMANNAN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 10; INTERLEUKIN 12;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COLONY FORMING UNIT; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; FEMALE; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOREGULATION; IN VITRO STUDY; INFECTION SENSITIVITY; INNATE IMMUNITY; LUNG ALVEOLUS MACROPHAGE; LUNG INFECTION; LUNG INFILTRATE; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE;

ANIMALS; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DISEASE SUSCEPTIBILITY; MACROPHAGES, ALVEOLAR; MICE; MICE, INBRED BALB C; MICE, INBRED CBA; TH1 CELLS; TH2 CELLS;

EID: 34249884492     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.00094-07     Document Type: Article

References (77)

1. Aguirre, K. M., G. W. Gibson, and L. L. Johnson. 1998. Decreased resistance to primary intravenous Cryptococcus neoformans infection in aged mice despite adequate resistance to intravenous rechallenge. Infect. Immun. 66:4018-4024.
2. Alvarez, M., and A. Casadevall. 2006. Phagosome extrusion and host-cell survival after Cryptococcus neoformans phagocytosis by macrophages. Curr. Biol. 16:2161-2165.
3. Arora, S., Y. Hernandez, J. R. Erb-Downward, R. A. McDonald, G. B. Toews, and G. B. Huffnagle. 2005. Role of IFN-gamma in regulating T2 immunity and the development of alternatively activated macrophages during allergic bronchopulmonary mycosis. J. Immunol. 174:6346-6356.
4. Bava, A. J., J. Afeltra, R. Negroni, and R. A. Diez. 1995. Interferon gamma increases survival in murine experimental cryptococcosis. Rev. Inst. Med. Trop. Sao Paulo 37:391-396.
5. Blackstock, R., K. L. Buchanan, R. Cherniak, T. G. Mitchell, B. Wong, A. Bartiss, L. Jackson, and J. W. Murphy. 1999. Pathogenesis of Cryptococcus neoformans is associated with quantitative differences in multiple virulence factors. Mycopathologia 147:1-11.
6. Casadevall, A., W. Cleare, M. Feldmesser, A. Glatman-Freedman, D. L. Goldman, T. R. Kozel, N. Lendvai, J. Mukherjee, L. A. Pirofski, J. Rivera, A. L. Rosas, M. D. Scharff, P. Valadon, K. Westin, and Z. Zhong. 1998. Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies. Antimicrob. Agents Chemother. 42:1437-1446.
7. Casadevall, A., J. Mukherjee, S. J. Devi, R. Schneerson, J. B. Robbins, and M. D. Scharff. 1992. Antibodies elicited by a Cryptococcus neoformans- tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection. J. Infect. Dis. 165:1086-1093.
8. Casadevall, A., J. Mukherjee, and M. D. Scharff. 1992. Monoclonal antibody based ELISAs for cryptococcal polysaccharide. J. Immunol. Methods 154:27-35.
9. Casadevall, A., and J. R. Perfect. 1998. Cryptococcus neoformans. ASM Press, Washington, DC.
10. Casadevall, A., and L. A. Pirofski. 2003. The damage-response framework of microbial pathogenesis. Nat. Rev. Microbiol. 1:17-24.
11. Cleare, W., and A. Casadevall. 1998. The different binding patterns of two immunoglobulin M monoclonal antibodies to Cryptococcus neoformans serotype A and D strains correlate with serotype classification and differences in functional assays. Clin. Diagn. Lab. Immunol. 5:125-129.
12. Clemens, K. V., J. E. Lutz, and D. A. Stevens. 2001. Efficacy of recombinant gamma interferon for treatment of systemic cryptococcosis in SCID mice. Antimicrob. Agents Chemother. 45:686-689.
13. Corbel, M. J., and S. M. Eades. 1976. The relative susceptibility of New Zealand black and CBA mice to infection with opportunistic fungal pathogens. Sabouraudia 14:17-32.
14. Curtis, J. L., G. B. Huffnagle, G. H. Chen, M. L. Warnock, M. R. Gyetko, R. A. McDonald, P. J. Scott, and G. B. Toews. 1994. Experimental murine pulmonary cryptococcosis. Differences in pulmonary inflammation and lymphocyte recruitment induced by two encapsulated strains of Cryptococcus neoformans. Lab. Invest. 71:113-126.
15. Chang, Y. C., M. F. Stins, M. J. McCaffery, G. F. Miller, D. R. Pare, T. Dam, M. Paul-Satyaseela, K. S. Kim, and K. J. Kwon-Chung. 2004. Cryptococcal yeast cells invade the central nervous system via transcellular penetration of the blood-brain barrier. Infect. Immun. 72:4985-4995.
16. Charlier, C., F. Chretien, M. Baudrimont, E. Mordelet, O. Lortholary, and F. Dromer. 2005. Capsule structure changes associated with Cryptococcus neoformans crossing of the blood-brain barrier. Am. J. Pathol. 166:421-432.
17. Chen, G. H., R. A. McDonald, J. C. Wells, G. B. Huffnagle, N. W. Lukacs, and G. B. Toews. 2005. The gamma interferon receptor is required for the protective pulmonary inflammatory response to Cryptococcus neoformans. Infect. Immun. 73:1788-1796.
18. Decken, K., G. Kohler, K. Palmer-Lehmann, A. Wunderlin, F. Mattner, J. Magram, M. K. Gately, and G. Alber. 1998. Interleukin-12 is essential for a protective Th1 response in mice infected with Cryptococcus neoformans. Infect. Immun. 66:4994-5000.
19. Dromer, F., J. Charreire, A. Contrepois, C. Carbon, and P. Yeni. 1987. Protection of mice against experimental cryptococcosis by anti-Cryptococcus neoformans monoclonal antibody. Infect. Immun. 55:749-752.
20. Feldmesser, M., Y. Kress, P. Novikoff, and A. Casadevall. 2000. Cryptococcus neoformans is a facultative intracellular pathogen in murine pulmonary infection. Infect. Immun. 68:4225-4237.
21. Flesch, I. E., G. Schwamberger, and S. H. Kaufmann. 1989. Fungicidal activity of IFN-gamma-activated macrophages. Extracellular killing of Cryptococcus neoformans. J. Immunol. 142:3219-3224.
22. Franzot, S. P., J. Mukherjee, R. Cherniak, L. C. Chen, J. S. Hamdan, and A. Casadevall. 1998. Microevolution of a standard strain of Cryptococcus neoformans resulting in differences in virulence and other phenotypes. Infect. Immun. 66:89-97.
23. Ganendren, R., E. Carter, T. Sorrell, F. Widmer, and L. Wright. 2006. Phospholipase B activity enhances adhesion of Cryptococcus neoformans to a human lung epithelial cell line. Microbes Infect. 8:1006-1015.
24. Goldman, D. L., J. Davis, F. Bommarito, X. Shao, and A. Casadevall. 2006. Enhanced allergic inflammation and airway responsiveness in rats with chronic Cryptococcus neoformans infection: potential role for fungal pulmonary infection in the pathogenesis of asthma. J. Infect. Dis. 193:1178-1186.
25. Goodner, K., and F. L. J. Horsfall. 1935. The protective action of type I antipneumococcus serum in mice. I. The quantitative aspects of the mouse protection test. J. Exp. Med. 62:359-374.
26. Hill, J. O., and A. G. Hannsen. 1991. Intrapulmonary growth and dissemination of an avirulent strain of Cryptococcus neoformans in mice depleted of CD4+ or CD8+ T cells. J. Exp. Med. 173:755-758.
27. Hoag, K. A., M. F. Lipscomb, A. A. Izzo, and N. E. Street. 1997. IL-12 and IFN-gamma are required for initiating the protective Th1 response to pulmonary cryptococcosis in resistant C.B-17 mice. Am. J. Respir. Cell Mol. Biol. 17:733-739.
28. Huffnagle, G. B. 1996. Role of cytokines in T cell immunity to a pulmonary Cryptococcus neoformans infection. Biol. Signals 5:215-222.
29. Huffnagle, G. B., M. B. Boyd, N. E. Street, and M. F. Lipscomb. 1998. IL-5 is required for eosinophil recruitment, crystal deposition, and mononuclear cell recruitment during a pulmonary Cryptococcus neoformans infection in genetically susceptible mice (C57BL/6). J. Immunol. 160:2393-2400.
30. Huffnagle, G. B., J. L. Yates, and M. F. Lipscomb. 1991. Immunity to a pulmonary Cryptococcus neoformans infection requires both CD4+ and CD8+ T cells. J. Exp. Med. 173:793-800.
31. Huffnagle, G. B., J. L. Yates, and M. F. Lipscomb. 1991. T cell-mediated immunity in the lung: a Cryptococcus neoformans pulmonary infection model using SCID and athymic nude mice. Infect. Immun. 59:1423-1433.
32. Kawakami, K., Y. Koguchi, M. H. Qureshi, T. Zhang, Y. Kinjo, S. Yara, K. Uezu, K. Shibuya, S. Naoe, and A. Saito. 2002. Anti-CD11 b monoclonal antibody suppresses brain dissemination of Cryptococcus neoformans in mice. Microbiol. Immunol. 46:181-186.
33. Kawakami, K., M. H. Qureshi, Y. Koguchi, K. Nakajima, and A. Saito. 1999. Differential effect of Cryptococcus neoformans on the production of IL-12p40 and IL-10 by murine macrophages stimulated with lipopolysaccharide and gamma interferon. FEMS Microbiol. Lett. 175:87-94.
34. Kawakami, K., M. Tohyama, K. Teruya, N. Kudeken, Q. Xie, and A. Saito. 1996. Contribution of interferon-gamma in protecting mice during pulmonary and disseminated infection with Cryptococcus neoformans. FEMS Immunol. Med. Microbiol. 13:123-130.
35. Kawakami, K., M. Tohyama, Q. Xie, and A. Saito. 1996. IL-12 protects mice against pulmonary and disseminated infection caused by Cryptococcus neoformans. Clin. Exp. Immunol. 104:208-214.
36. Kozel, T. R., W. F. Gulley, and J. Cazin, Jr. 1977. Immune response to Cryptococcus neoformans soluble polysaccharide: immunological unresponsiveness. Infect. Immun. 18:701-707.
37. Lindell, D. M., T. A. Moore, R. A. McDonald, G. B. Toews, and G. B. Huffnagle. 2005. Generation of antifungal effector CD8+ T cells in the absence of CD4+ T cells during Cryptococcus neoformans infection. J. Immunol. 174:7920-7928.
38. Lovchik, J. A., C. R. Lyons, and M. F. Lipscomb. 1995. A role for gamma interferon-induced nitric oxide in pulmonary clearance of Cryptococcus neoformans. Am. J. Respir. Cell Mol. Biol. 13:116-124.
39. Maitta, R. W., K. Datta, Q. Chang, R. X. Luo, B. Witover, K. Subramaniam, and L. A. Pirofski. 2004. Protective and nonprotective human immunoglobulin M monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles. Infect. Immun. 72:4810-4818.
40. Mansour, M. K., L. E. Yauch, J. B. Roltman, and S. M. Levitz. 2004. Protective efficacy of antigenic fractions in mouse models of cryptococcosis. Infect. Immun. 72:1746-1754.
41. McClelland, E. E., P. Bernhardt, and A. Casadevall. 2006. Estimating the relative contributions of virulence factors for pathogenic microbes. Infect. Immun. 74:1500-1504.
42. McFadden, D. C., and A. Casadevall. 2001. Capsule and melanin synthesis in Cryptococcus neoformans. Med. Mycol. 39(Suppl. 1):19-30.
43. McLean, G. R., M. Torres, N. Elguezabal, A. Nakouzi, and A. Casadevall. 2002. Isotype can affect the fine specificity of an antibody for a polysaccharide antigen. J. Immunol. 169:1379-1386.
44. Mednick, A. J., M. Feldmesser, J. Rivera, and A. Casadevall. 2003. Neutropenia alters lung cytokine production in mice and reduces their susceptibility to pulmonary cryptococcosis. Eur. J. Immunol. 33:1744-1753.
45. Mody, C. H., M. F. Lipscomb, N. E. Street, and G. B. Toews. 1990. Depletion of CD4+ (L3T4+) lymphocytes in vivo impairs murine host defense to Cryptococcus neoformans. J. Immunol. 144:1472-1477.
46. Mody, C. H., C. L. Tyler, R. G. Sitrin, C. Jackson, and G. B. Toews. 1991. Interferon-gamma activates rat alveolar macrophages for anticryptococcal activity. Am. J. Respir. Cell Mol. Biol. 5:19-26.
47. Monari, C., C. Retini, B. Palazzetti, F. Bistoni, and A. Vecchiarelli. 1997. Regulatory role of exogenous IL-10 in the development of immune response versus Cryptococcus neoformans. Clin. Exp. Immunol. 109:242-247.
48. Mukherjee, J., A. Casadevall, and M. D. Scharff. 1993. Molecular characterization of the humoral responses to Cryptococcus neoformans infection and glucuronoxylomannan-tetanus toxoid conjugate immunization. J. Exp. Med. 177:1105-1116.
49. Mukherjee, J., G. Nussbaum, M. D. Scharff, and A. Casadevall. 1995. Protective and nonprotective monoclonal antibodies to Cryptococcus neoformans originating from one B cell. J. Exp. Med. 181:405-409.
50. Mukherjee, J., L. A. Pirofski, M. D. Scharff, and A. Casadevall. 1993. Antibody-mediated protection in mice with lethal intracerebral Cryptococcus neoformans infection. Proc. Natl. Acad. Sci. USA 90:3636-3640.
51. Mukherjee, J., M. D. Scharff, and A. Casadevall. 1992. Protective murine monoclonal antibodies to Cryptococcus neoformans. Infect. Immun. 60:4534-4541.
52. Mukherjee, J., M. D. Scharff, and A. Casadevall. 1995. Variable efficacy of passive antibody administration against diverse Cryptococcus neoformans strains. Infect. Immun. 63:3353-3359.
53. Mukherjee, S., S. Lee, J. Mukherjee, M. D. Scharff, and A. Casadevall. 1994. Monoclonal antibodies to Cryptococcus neoformans capsular polysaccharide modify the course of intravenous infection in mice. Infect. Immun. 62:1079-1088.
54. Murphy, J. W., and G. C. Cozad. 1972. Immunological unresponsiveness induced by cryptococcal capsular polysaccharide assayed by the hemolytic plaque technique. Infect. Immun. 5:896-901.
55. Nosanchuk, J. D., and A. Casadevall. 2003. The contribution of melanin to microbial pathogenesis. Cell. Microbiol. 5:203-223.
56. Noverr, M. C., P. R. Williamson, R. S. Fajardo, and G. B. Huffnagle. 2004. CNLAC1 is required for extrapulmonary dissemination of Cryptococcus neoformans but not pulmonary persistence. Infect. Immun. 72:1693-1699.
57. Nussbaum, G., W. Cleare, A. Casadevall, M. D. Scharff, and P. Valadon. 1997. Epitope location in the Cryptococcus neoformans capsule is a determinant of antibody efficacy. J. Exp. Med. 185:685-694.
58. Retini, C., T. R. Kozel, D. Pietrella, C. Monari, F. Bistoni, and A. Vecchiarelli. 2001. Interdependency of interleukin-10 and interleukin-12 in regulation of T-cell differentiation and effector function of monocytes in response to stimulation with Cryptococcus neoformans. Infect. Immun. 69:6064-6073.
59. Rivera, J., and A. Casadevall. 2005. Mouse genetic background is a major determinant of isotype-related differences for antibody-mediated protective efficacy against Cryptococcus neoformans. J. Immunol. 174:8017-8026.
60. Rivera, J., O. Zaragoza, and A. Casadevall. 2005. Antibody-mediated protection against Cryptococcus neoformans pulmonary infection is dependent on B cells. Infect. Immun. 73:1141-1150.
61. Salkowski, C. A., K. F. Bartizal, M. J. Balish, and E. Balish. 1987. Colonization and pathogenesis of Cryptococcus neoformans in gnotobiotic mice. Infect. Immun. 55:2000-2005.
62. Sanford, J. E., D. M. Lupan, A. M. Schlageter, and T. R. Kozel. 1990. Passive immunization against Cryptococcus neoformans with an isotype-switch family of monoclonal antibodies reactive with cryptococcal polysaccharide. Infect. Immun. 58:1919-1923.
63. Santangelo, R., H. Zoellner, T. Sorrell, C. Wilson, C. Donald, J. Djordjevic, Y. Shounan, and L. Wright. 2004. Role of extracellular phospholipases and mononuclear phagocytes in dissemination of cryptococcosis in a murine model. Infect. Immun. 72:2229-2239.
64. Shao, X., A. Mednick, M. Alvarez, N. van Rooijen, A. Casadevall, and D. L. Goldman. 2005. An innate immune system cell is a major determinant of species-related susceptibility differences to fungal pneumonia. J. Immunol. 175:3244-3251.
65. Shea, J. M., T. B. Kechichian, C. Luberto, and M. Del Poeta. 2006. The cryptococcal enzyme inositol phosphosphingolipid-phospholipase C confers resistance to the antifungal effects of macrophages and promotes fungal dissemination to the central nervous system. Infect. Immun. 74:5977-5988.
66. Shoham, S., and S. M. Levitz. 2005. The immune response to fungal infections. Br. J. Haematol. 129:569-582.
67. Taborda, C. P., and A. Casadevall. 2001. Immunoglobulin M efficacy against Cryptococcus neoformans: mechanism, dose dependence, and prozone-like effects in passive protection experiments. J. Immunol. 166:2100-2107.
68. Taborda, C. P., J. Rivera, O. Zaragoza, and A. Casadevall. 2003. More is not necessarily better: prozone-like effects in passive immunization with IgG. J. Immunol. 170:3621-3630.
69. Torres, M., R. May, M. D. Scharff, and A. Casadevall. 2005. Variable-region-identical antibodies differing in isotype demonstrate differences in fine specificity and idiotype. J. Immunol. 174:2132-2142.
70. Tucker, S. C., and A. Casadevall. 2002. Replication of Cryptococcus neoformans in macrophages is accompanied by phagosomal permeabilization and accumulation of vesicles containing polysaccharide in the cytoplasm. Proc. Natl. Acad. Sci. USA 99:3165-3170.
71. Vecchiarelli, A. 2005. The cellular responses induced by the capsular polysaccharide of Cryptococcus neoformans differ depending on the presence or absence of specific protective antibodies. Curr. Mol. Med. 5:413-420.
72. Vecchiarelli, A. 2000. Immunoregulation by capsular components of Cryptococcus neoformans. Med. Mycol. 38:407-417.
73. Vecchiarelli, A., C. Retini, C. Monari, C. Tascini, F. Bistoni, and T. R. Kozel. 1996. Purified capsular polysaccharide of Cryptococcus neoformans induces interleukin-10 secretion by human monocytes. Infect. Immun. 64:2846-2849.
74. Yuan, R., A. Casadevall, G. Spira, and M. D. Scharff. 1995. Isotype switching from IgG3 to IgG1 converts a nonprotective murine antibody to Cryptococcus neoformans into a protective antibody. J. Immunol. 154:1810-1816.
75. Yuan, R. R., G. Spira, J. Oh, M. Paizi, A. Casadevall, and M. D. Scharff. 1998. Isotype switching increases efficacy of antibody protection against Cryptococcus neoformans infection in mice. Infect. Immun. 66:1057-1062.
76. Zaragoza, O., and A. Casadevall. 2004. Antibodies produced in response to Cryptococcus neoformans pulmonary infection in mice have characteristics of nonprotective antibodies. Infect. Immun. 72:4271-4274.
77. Zaragoza, O., C. P. Taborda, and A. Casadevall. 2003. The efficacy of complement-mediated phagocytosis of Cryptococcus neoformans is dependent on the location of C3 in the polysaccharide capsule and involves both direct and indirect C3-mediated interactions. Eur. J. Immnunol. 33:1957-1967.